$1.27
7.30% day before yesterday
Nasdaq, Nov 08, 10:00 pm CET
ISIN
US68236P1075
Symbol
ONCT
Sector
Industry

Oncternal Therapeutics Inc Stock price

$1.27
+0.02 1.90% 1M
-7.29 85.15% 6M
-9.45 88.16% YTD
-5.33 80.75% 1Y
-86.53 98.55% 3Y
-113.73 98.90% 5Y
-781.19 99.84% 10Y
Nasdaq, Closing price Fri, Nov 08 2024
-0.10 7.30%
ISIN
US68236P1075
Symbol
ONCT
Sector
Industry

Key metrics

Market capitalization $3.76m
Enterprise Value $-10.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.40
EV/Sales (TTM) EV/Sales -4.92
P/S ratio (TTM) P/S ratio 1.74
P/B ratio (TTM) P/B ratio 0.41
Revenue growth (TTM) Revenue growth 227.92%
Revenue (TTM) Revenue $2.16m
EBIT (operating result TTM) EBIT $-35.96m
Free Cash Flow (TTM) Free Cash Flow $-26.63m
Cash position $14.58m
EPS (TTM) EPS $-11.69
P/E forward negative
P/S forward 2.29
EV/Sales forward negative
Short interest 0.59%
Show more

Is Oncternal Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,906 stocks worldwide.

Oncternal Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Oncternal Therapeutics Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Oncternal Therapeutics Inc forecast:

Buy
50%
Hold
50%

Financial data from Oncternal Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.16 2.16
227% 227%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
1% 1%
571%
- Research and Development Expense 26 26
19% 19%
1,194%
-36 -36
18% 18%
-1,665%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
18% 18%
-1,665%
Net Profit -35 -35
17% 17%
-1,601%

In millions USD.

Don't miss a Thing! We will send you all news about Oncternal Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncternal Therapeutics Inc Stock News

Neutral
Seeking Alpha
3 months ago
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the On...
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2024 financial results.
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p...
More Oncternal Therapeutics Inc News

Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.

Head office United States
CEO James Breitmeyer
Employees 27
Founded 1997
Website www.oncternal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today